The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January. That’s ...

Finding oneself at an advanced stage of disease is devastating and may diminish one’s hope for the future. Participation in a ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and ...

In the study, MILTON was used to analyse 3,200 diseases and achieved a high prediction score for 1,091 of them. It can be ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...